Saniona AB (SE:SANION)
:SANION
Want to see SE:SANION full AI Analyst Report?
Top Page
Saniona AB
(SANION)
Select Model
Select Model
Rating:59Neutral
Price Target:
kr14.50
▼(-31.28% Downside)
Action:ReiteratedDate:03/04/26
The score is held back primarily by weak technicals (strong downtrend with negative momentum), partially offset by improved recent financial performance (profitability and cash flow turning positive, debt-free balance sheet) and an attractive P/E valuation.
Positive Factors
Debt-free balance sheet
A zero-debt position and meaningful equity in 2025 materially improve financial flexibility for a development-stage biotech. This reduces refinancing risk, lowers fixed financing costs and preserves optionality to fund R&D or partnerships over the next several months without urgent external debt.
Negative Factors
Revenue volatility
Large year-over-year revenue swings reflect dependence on timing of program milestones or partner receipts, undermining predictability of cash flow and margins. This makes budgeting R&D and commercialization investments harder and raises the risk of future earnings volatility.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A zero-debt position and meaningful equity in 2025 materially improve financial flexibility for a development-stage biotech. This reduces refinancing risk, lowers fixed financing costs and preserves optionality to fund R&D or partnerships over the next several months without urgent external debt.
Read all positive factors
Saniona AB (SANION) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr1.93B
Dividend YieldN/A
Average Volume (3M)1.06M
Price to Earnings (P/E)9.6
Beta (1Y)-0.18
Revenue Growth29.80%
EPS Growth25.42%
CountrySE
Employees22
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.30
Shares Outstanding138,030,140
10 Day Avg. Volume913,988
30 Day Avg. Volume1,064,614
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)4.30
Price to Sales (P/S)6.29
P/FCF Ratio13.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr11.00M
Saniona AB Business Overview & Revenue Model
Company Description
Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark. The company's products include Tesofensine, a monoamine reuptake inhi...
How the Company Makes Money
null...
Saniona AB Financial Statement Overview
Summary
Income Statement
64
Positive
Balance Sheet
74
Positive
Cash Flow
67
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 434.40M | 334.67M | 16.84M | 15.28M | 10.48M |
| Gross Profit | 274.72M | 329.58M | 11.78M | 10.81M | 5.85M |
| EBITDA | 281.45M | 251.90M | -68.28M | -198.41M | -398.86M |
| Net Income | 284.67M | 188.71M | -95.81M | -245.36M | -410.90M |
Balance Sheet | |||||
| Total Assets | 679.74M | 339.73M | 64.14M | 153.70M | 440.25M |
| Cash, Cash Equivalents and Short-Term Investments | 580.82M | 303.26M | 30.96M | 111.71M | 356.86M |
| Total Debt | 0.00 | 10.50M | 71.41M | 81.52M | 99.77M |
| Total Liabilities | 44.58M | 107.92M | 86.08M | 100.99M | 158.25M |
| Stockholders Equity | 635.16M | 231.82M | -21.94M | 52.71M | 282.00M |
Cash Flow | |||||
| Free Cash Flow | 200.30M | 249.07M | -85.66M | -282.52M | -346.52M |
| Operating Cash Flow | 273.86M | 249.20M | -85.53M | -281.54M | -345.04M |
| Investing Cash Flow | -77.62M | -124.00K | -129.00K | 6.84M | 43.16M |
| Financing Cash Flow | 108.19M | 23.25M | -7.97M | -20.52M | 50.60M |
Saniona AB Technical Analysis
Negative
21.10
Price Trends
18.44
Negative
19.93
Negative
15.92
Negative
Market Momentum
-0.59
Negative
43.52
Neutral
54.49
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SANION, the sentiment is Negative. The current price of 21.1 is above the 20-day moving average (MA) of 15.62, above the 50-day MA of 18.44, and above the 200-day MA of 15.92, indicating a bearish trend. The MACD of -0.59 indicates Negative momentum. The RSI at 43.52 is Neutral, neither overbought nor oversold. The STOCH value of 54.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SANION.
Saniona AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | kr1.93B | 9.60 | 167.77% | ― | 29.80% | 25.42% | |
55 Neutral | kr945.22M | 7.07 | 81.19% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr505.76M | -4.37 | ― | ― | 125.10% | 29.02% | |
49 Neutral | kr226.66M | -44.78 | -16.90% | ― | -23.33% | ― | |
45 Neutral | kr937.55M | -10.42 | -58.41% | ― | ― | -3.80% | |
45 Neutral | kr1.22B | -7.05 | -35.03% | ― | ― | 46.92% |
* Healthcare Sector Average
SE:SANION
Saniona AB
13.98
6.62
89.95%
SE:ONCO
Oncopeptides AB
1.30
-0.42
-24.41%
SE:SYNACT
SynAct Pharma AB
17.58
-2.52
-12.54%
SE:XBRANE
Xbrane Biopharma AB
11.00
-13.38
-54.87%
SE:XSPRAY
Xspray Pharma AB
26.65
-6.59
-19.82%
SE:CANTA
Cantargia AB
3.80
2.17
133.25%
Saniona AB Corporate Events
Saniona Publishes Comprehensive 2025 Annual Report Covering Operations, Financials and Governance
Apr 30, 2026
Saniona AB has published its 2025 annual report, providing a comprehensive overview of the year’s activities, including a CEO letter, pipeline update, scientific background, share performance, five-year summary, and risk factors. The report ...
Saniona convenes 2026 AGM with governance and long-term incentive plan on agenda
Apr 24, 2026
Saniona AB has called its annual shareholders’ meeting for 27 May 2026 in Malmö, setting out formal participation requirements including Euroclear Sweden registration by 19 May and advance notice by 21 May, as well as rules for proxy re...
Saniona Steps Up Investor Outreach With Busy Spring Conference Schedule
Mar 12, 2026
Saniona will present its programs and strategy at a series of investor and partnering conferences across Europe and the U.S. during the spring and summer, including events in Stockholm, New York, Copenhagen and San Diego. The company’s activ...
Saniona Shifts From Partnership-Driven Gains to Clinical Execution in 2025
Feb 26, 2026
Saniona reported full-year 2025 revenue of SEK 434.4 million, up from SEK 334.7 million, with operating profit rising to SEK 271.0 million and net profit to SEK 284.6 million, supported by a solid cash position of SEK 580.8 million. However, the f...
Saniona Sets February Investor Call to Present Q4 Results and Pipeline Update
Feb 20, 2026
Saniona AB, a Copenhagen-based clinical-stage biopharmaceutical company listed on the Nasdaq Stockholm Main Market, develops treatments for neurological and psychiatric disorders, including pipeline assets for paediatric epilepsy, epilepsy, and ma...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.